Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Is the reported $400 billion AstraZeneca-Bristol Myers Squibb megamerger a slam dunk or a disaster waiting to happen?

MSN

Aug 14, 2026 at 03:10 AM

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

Login to unlock79characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

Feb 10, 2026 at 01:42 PMGlobal news you need to know before the U.S. stock market opens on Tuesday
Feb 10, 2026 at 08:30 AMAfter investing $18.5 billion to partner with Stone Group, AstraZeneca's earnings per share are expected to increase by …
Jan 7, 2026 at 08:30 AMWill GLP-1 spillover and AI empowerment make biomedicine the "alternative" for tech stocks in 2026?
Nov 11, 2025 at 01:51 PMConsolidating its position as the "largest heavyweight stock" in the UK market, pharmaceutical giant Astrazeneca's stock…

Related Stocks

AstraZeneca

USAZN

+0.33%

Bristol Myers Squibb

USBMY

-0.17%

AstraZeneca PLC

UKAZN

LongbridgeAI